Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Current Assets (2016 - 2025)

Anaptysbio filings provide 10 years of Current Assets readings, the most recent being $350.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Current Assets fell 18.9% year-over-year to $350.2 million, compared with a TTM value of $350.2 million through Dec 2025, down 18.9%, and an annual FY2025 reading of $350.2 million, down 18.9% over the prior year.
  • Current Assets hit $350.2 million in Q4 2025 for Anaptysbio, up from $330.6 million in the prior quarter.
  • The five-year high for Current Assets was $553.9 million in Q4 2021, with the low at $291.9 million in Q2 2025.
  • Median Current Assets over the past 5 years was $417.4 million (2023), compared with a mean of $412.8 million.
  • The sharpest move saw Current Assets surged 39.67% in 2021, then fell 26.31% in 2025.
  • Year by year, Current Assets stood at $553.9 million in 2021, then dropped by 19.26% to $447.2 million in 2022, then decreased by 9.03% to $406.8 million in 2023, then grew by 6.16% to $431.9 million in 2024, then dropped by 18.9% to $350.2 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $350.2 million, $330.6 million, and $291.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.